Logo

Adagio Collaborates with Biocon to Provide COVID-19 Ab Treatment to Patients in India and Other Emerging Markets

Share this

Adagio Collaborates with Biocon to Provide COVID-19 Ab Treatment to Patients in India and Other Emerging Markets

Shots:

  • The companies collaborated for Adagio’s ADG20 for both the treatment & prevention of COVID-19 as monothx. or combination regimen
  • Biocon will gain rights to manufacture & commercialize ADG20 for COVID-19 in India and select emerging markets based on the commercial process developed for ADG20. The company will have the access to Adagio’s ongoing P-II/III study data & to its anticipated EUA along with regulatory submissions- supporting the approval or EUA in India & other emerging markets
  • ADG20 is currently being evaluated in two studies. The STAMP trial to evaluate ADG20 for non-hospitalized COVID-19 patients and the EVADE trial to evaluate ADG20 for the prevention of COVID-19

  | Ref: Businesswire | Image: Adagio

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions